View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 16, 2022

Inmagene receives FDA clearance for Phase I trial of immunological disease BTK inhibitor asset

A small molecule BTK inhibitor, IMG-004 is being developed to potentially treat immunological diseases.

Inmagene Biopharmaceuticals’ drug candidate, IMG-004, secured clearance from the US Food and Drug Administration (FDA) to be investigated in a Phase I clinical trial.

A reversible, non-covalent, third-generation small molecule inhibitor of Bruton Tyrosine Kinase (BTK), IMG-004 is being developed for the potential treatment of immunological diseases. IMG-004 was discovered by Hutchmed, while Inmagene obtained the rights to develop it at the candidate stage.

It is a selective and brain permeable drug intended for inflammatory and autoimmune ailments that need long-term treatment.

A non-receptor intracytoplasmic tyrosine kinase, BTK belongs to the Tec family of protein tyrosine kinases. It is involved in innate as well as adaptive immune responses linked to various immune-mediated ailments. 

Due to BTK’s key role in immunity pathways, BTK inhibitors could provide a potential treatment approach for treating various inflammatory and autoimmune diseases.

The double-blind, placebo-controlled, randomised, single and multiple dose escalation trial will enrol healthy participants.

Analysing the safety, tolerability, pharmacokinetics and pharmacodynamics of IMG-004 in healthy participants is the goal of the trial.

Inmagene Biopharmaceuticals chief development officer Dr Jean-Louis Saillot said: “BTK inhibition is an attractive target for a variety of inflammatory and autoimmune diseases, based on demonstrated activity or its current evaluation in clinical trials.

“IMG-004’s improved activity, selectivity, and pharmacokinetic profile in preclinical studies compared to those of other BTK inhibitors point toward a best-in-class potential.”

A clinical-stage biotechnology company, Inmagene develops new therapies to treat immunology-linked diseases.

It is building a pipeline of approximately 20 drug development programmes.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena